Purple Biotech

PPBT · TEL

$1.08+$0.03 (+2.86%)TodayMarket closed · Oct 23, 7:44 PM ET

Prev close $1.05

About PPBT

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 10 full-time employees. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Employees: 10
Headquarters: Rehovot, Central(HaMerkaz)
Listed: Sep 3, 1978
Sector: Health Care
Industry: Pharmaceuticals
Website: purple-biotech.com

Leadership

Purple Biotech executives
Name	Title	Since	Age
Eric Rowinsky	—	2019	67
Itzhak Israel	—	2012	39
Gil Efron	—	—	57
Gil Ben-Menachem	—	—	49
Avraham Ben-Tzvi	—	—	52
Yisrael Gewirtz	—	—	46
Bertrand Liang	—	—	—
Hadas Reuveni	—	—	50
Michael Schickler	—	—	—
Robert Gagnon	—	—	49
Suzana Nahum-Zilberberg	—	—	50
Simcha Rock	—	2013	68
Ido Agmon	—	—	40
Steven Steinberg	—	—	56
Revital Stern-Raff	—	—	44
Ran Tzror	—	—	36
Arie Weber	—	—	69

Similar companies

Companies in the same industry as Purple Biotech

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.